BofA upgraded Apollo Medical to Buy from Neutral with a price target of $55, up from $44. The firm sees an inflection point in the growth story, with “high confidence” in the path to sustaining 30%-40%-plus revenue and 20%-plus EBITDA growth through at least 2026. As a result, it is raising its estimates above the Street, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AMEH: